Whereas a lack of assessment of the HER-2/neu status deprives breast cancer patients from beneficial treatment, a false positive diagnosis of gene amplification could lead to an unnecessary expensive therapy with multiple possible side effects, including cardiac dysfunction [28]. This evidence concerns the gene ERBB2 and breast cancer.